PECAM1 and neoplasm: In sequential therapy evaluation, for KiCa-Pt58, P→E yielded greatest reductions in tumor weight (<i>p</i> < 0.01), lung metastases (<i>p</i> < 0.01), Ki67+ proliferation, CD31+ angiogenesis, and PD-L1 expression versus control; E→S and S→E were also effective.